| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 41 | Compositions and methods comprising KLK3 of FOLH1 antigen | US11798177 | 2007-05-10 | US20070253976A1 | 2007-11-01 | Yvonne Paterson; John Rothman; Vafa Shahabi |
| The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same. | ||||||
| 42 | Forms of prostate specific antigens and methods for their detection | US09792692 | 2001-02-23 | US07288636B2 | 2007-10-30 | Stephen D. Mikolajczyk; Harry G. Rittenhouse; Abhay Kumar; Mohammad S. Saedi; Robert L. Wolfert |
| Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer. | ||||||
| 43 | VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS | EP14802175.1 | 2014-10-17 | EP3062815A1 | 2016-09-07 | BINDER, Joseph John; CHO, Helen Kim |
| The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers. | ||||||
| 44 | FORMS OF PROSTATE SPECIFIC ANTIGENS AND METHODS FOR THEIR DETECTION | EP02750561.9 | 2002-02-22 | EP1392719B1 | 2009-04-22 | MIKOLAJCZYK, Stephen, D.; SAEDI, Mohammad, S.; RITTENHOUSE, Harry, G.; KUMAR, Abhay; WOLFERT, Robert, L. |
| Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer. | ||||||
| 45 | FORMS OF PROSTATE SPECIFIC ANTIGENS AND METHODS FOR THEIR DETECTION | EP02750561 | 2002-02-22 | EP1392719A4 | 2005-10-19 | MIKOLAJCZYK STEPHEN D; SAEDI MOHAMMAD S; RITTENHOUSE HARRY G; KUMAR ABHAY; WOLFERT ROBERT L |
| Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer. | ||||||
| 46 | Cell surface prostate cancer antigen for diagnosis | US15111973 | 2015-01-16 | US10151754B2 | 2018-12-11 | Bradley Walsh; Douglas Campbell; Irene Justiniano Fuenmayor; Aline Nocon; Julie Soon; Quach Truong; Sandra Wissmueller; Pamela Russell |
| The present invention provides compositions and methods of detecting prostate cancer in the body fluids or tissues of patients. Prostate cancer is detected by measuring the level of glypican-1 in a body fluid sample. In one embodiment prostate cancer is detected by contacting a body fluid sample with an anti-glypican-1 antibody, such as MIL-38. The invention includes kits for detection of prostate cancer in a body fluid sample, comprising an anti-glypican-1 antibody and glypican-1 standards. | ||||||
| 47 | FLUIDIC SYSTEMS AND METHODS FOR ANALYSES | US15787078 | 2017-10-18 | US20180085753A1 | 2018-03-29 | David Steinmiller; Vincent Linder |
| Fluidic systems and methods for analyses are provided. In some embodiments, systems and methods for improved measurement of absorbance/transmission through fluidic systems are described. Specifically, in one set of embodiments, optical elements are fabricated on one side of a transparent fluidic device opposite a series of fluidic channels. The optical elements may guide incident light passing through the device such that most of the light is dispersed away from specific areas of the device, such as intervening portions between the fluidic channels. By decreasing the amount of light incident upon these intervening portions, the amount of noise in the detection signal can be decreased when using certain optical detection systems. | ||||||
| 48 | Fluidic systems and methods for analyses | US15196975 | 2016-06-29 | US09827564B2 | 2017-11-28 | David Steinmiller; Vincent Linder |
| Fluidic systems and methods for analysis are provided. In some embodiments, systems and methods for improved measurement of absorbance/transmission through fluidic systems are described. Specifically, in one set of embodiments, optical elements are fabricated on one side of a transparent fluidic device opposite a series of fluidic channels. The optical elements may guide incident light passing through the device such that most of the light is dispersed away from specific areas of the device, such as intervening portions between the fluidic channels. By decreasing the amount of light incident upon these intervening portions, the amount of noise in the detection signal can be decreased when using certain optical detection systems. | ||||||
| 49 | RECOMBINANT T CELL RECEPTOR LIGAND COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CANCER | US15400587 | 2017-01-06 | US20170196957A1 | 2017-07-13 | Arthur A. Vandenbark; Roberto Meza-Romero; Richard Alexander; Elena Klyushnenkova |
| Disclosed herein are compositions and methods for treating or inhibiting prostate cancer. The compositions include a MHC molecule including covalently linked first and second domains, wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain, and a prostate specific antigen peptide covalently linked to the first domain. The methods include administering a disclosed MHC molecule to a subject with prostate cancer. | ||||||
| 50 | Compositions and methods comprising KLK3 or FOLH1 antigen | US14581217 | 2014-12-23 | US09549973B2 | 2017-01-24 | Yvonne Paterson; John Rothman; Vafa Shahabi |
| The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same. | ||||||
| 51 | Consensus Prostate Antigens, Nucleic Acid Molecule Encoding The Same And Vaccine And Uses Comprising The Same | US15207271 | 2016-07-11 | US20160361403A1 | 2016-12-15 | David Weiner; Jian Yan; Bernadette Ferraro; Niranjan Y. Sardesai; Mathura P. Ramanathan |
| Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided. | ||||||
| 52 | VECTORS FOR EXPRESSION OF PROSTATE-ASSOCIATED ANTIGENS | US15146578 | 2016-05-04 | US20160235829A1 | 2016-08-18 | Joseph John BINDER |
| The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers. | ||||||
| 53 | PROSTATE SPECIFIC ANTIGEN PROTEOLYTIC ACTIVITY FOR CLINICAL USE | US14863397 | 2015-09-23 | US20160097082A1 | 2016-04-07 | Dimitra Georganopoulou |
| Methods for predicting the outcome of and monitoring prostate cancer patients using prostate specific antigen (PSA) proteolytic activity (PPA) in combination with other molecular biomarkers or other parameters are described. Methods of determining sets of parameters for use in predicting the outcome of and monitoring of prostate cancer patients are also described. | ||||||
| 54 | COMPOSITIONS AND METHODS COMPRISING KLK3 OR FOLH1 ANTIGEN | US14581217 | 2014-12-23 | US20150335721A1 | 2015-11-26 | YVONNE PATERSON; JOHN ROTHMAN; VAFA SHAHABI |
| The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same. | ||||||
| 55 | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT INCLUDING FUSION PROTEIN | US14379104 | 2013-02-15 | US20150284444A1 | 2015-10-08 | Masami Watanabe; Hiromi Kumon; Yasutomo Nasu |
| An object of the present invention is to use fusion proteins of cancer-specific antigens and cytokines as a preventive or therapeutic agent for cancer. The present invention provides a pharmaceutical composition for the prevention or treatment of a cancer, comprising as active ingredients fusion proteins each comprising a cancer-specific antigen with a cytokine selected from the group consisting of human IL2 (hIL2), human IL4 (hIL4), human IL7 (hIL7), human GMCSF (hGMCSF), mouse IL4 (mIL4), and mouse GMCSF (mGMCSF). | ||||||
| 56 | STRUCTURES FOR CONTROLLING LIGHT INTERACTION WITH MICROFLUIDIC DEVICES | US14316069 | 2014-06-26 | US20150196908A9 | 2015-07-16 | David Steinmiller; Vincent Linder |
| Systems and methods for improved measurement of absorbance/transmission through fluidic systems are described. Specifically, in one set of embodiments, optical elements are fabricated on one side of a transparent fluidic device opposite a series of fluidic channels. The optical elements may guide incident light passing through the device such that most of the light is dispersed away from specific areas of the device, such as intervening portions between the fluidic channels. By decreasing the amount of light incident upon these intervening portions, the amount of noise in the detection signal can be decreased when using certain optical detection systems. | ||||||
| 57 | Consensus Prostate Antigens, Nucleic Acid Molecule Encoding The Same And Vaccine And Uses Comprising The Same | US14552030 | 2014-11-24 | US20150150957A1 | 2015-06-04 | David B. Weiner; Jian Yan; Bernadette Ferraro; Niranjan Y. Sardesai; Mathura P. Ramanathan |
| Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided. | ||||||
| 58 | URINARY BIOMARKER FOR USE IN TEST FOR PROSTATE CANCER | US14389320 | 2013-03-28 | US20150065373A1 | 2015-03-05 | Kenji Nakayama; Kazuharu Shimizu; Jun Utsumi; Takahiro Inoue; Osamu Ogawa |
| A novel method that enables prostate cancer testing that is noninvasive and more accurate than conventional methods is disclosed. The present inventors intensively analyzed urine samples from prostate cancer patients, and non-cancer subjects, who are free of prostate cancer, and, as a result, newly discovered urinary peptides that can be used as indicators in prostate cancer testing. Use of these urinary peptides as indicators enables various prostate cancer-related tests including detection of prostate cancer, discrimination between prostate cancer and benign prostatic hyperplasia, monitoring of a therapeutic effect of prostate cancer therapy and monitoring of postoperative recurrence. | ||||||
| 59 | Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same | US13883978 | 2011-11-14 | US08927692B2 | 2015-01-06 | David B Weiner; Jian Yan; Bernadette Ferraro; Niranjan Y Sardesai; Mathura P Ramanathan |
| Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided. | ||||||
| 60 | STRUCTURES FOR CONTROLLING LIGHT INTERACTION WITH MICROFLUIDIC DEVICES | US14316069 | 2014-06-26 | US20140308168A1 | 2014-10-16 | David Steinmiller; Vincent Linder |
| Systems and methods for improved measurement of absorbance/transmission through fluidic systems are described. Specifically, in one set of embodiments, optical elements are fabricated on one side of a transparent fluidic device opposite a series of fluidic channels. The optical elements may guide incident light passing through the device such that most of the light is dispersed away from specific areas of the device, such as intervening portions between the fluidic channels. By decreasing the amount of light incident upon these intervening portions, the amount of noise in the detection signal can be decreased when using certain optical detection systems. | ||||||
QQ群二维码
意见反馈
意见反馈